Invibes Advertising NV
PAR:ALINV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Invibes Advertising NV
PAR:ALINV
|
BE |
|
Kinnate Biopharma Inc
F:6KB
|
US |
|
C
|
Cuu Long Pharmaceutical JSC
VN:DCL
|
VN |
|
Alliance Healthcare Group Ltd
SGX:MIJ
|
SG |
|
Doganlar Mobilya Grubu Imalat Sanayi ve Ticaret AS
IST:DGNMO.E
|
TR |
|
Keros Therapeutics Inc
NASDAQ:KROS
|
US |
|
Anson Resources Ltd
ASX:ASN
|
AU |
|
Samsung SDS Co Ltd
KRX:018260
|
KR |
|
Talon International Inc
OTC:TALN
|
US |
|
Avidxchange Holdings Inc
NASDAQ:AVDX
|
US |
|
Gelstat Corp
OTC:GSAC
|
US |
|
10X Genomics Inc
NASDAQ:TXG
|
US |
|
Netscout Systems Inc
NASDAQ:NTCT
|
US |
|
M
|
Mediaco Holding Inc
NASDAQ:MDIA
|
US |
|
G
|
Ggumbi Inc
KOSDAQ:407400
|
KR |
|
S
|
Southern Steel Bhd
KLSE:SSTEEL
|
MY |
|
O
|
Oil India Ltd
BSE:533106
|
IN |
|
L
|
Loma Negra Compania Industrial Argentina SA
BCBA:LOMA
|
AR |
|
STM Group PLC
LSE:STM
|
IM |
|
Natco Pharma Ltd
NSE:NATCOPHARM
|
IN |
|
Itway SpA
MIL:ITW
|
IT |
|
Advanced Drainage Systems Inc
NYSE:WMS
|
US |
|
G
|
Gr Sarantis SA
ATHEX:SAR
|
GR |
|
D
|
DigiCo Infrastructure REIT
ASX:DGT
|
AU |
Income Statement
Earnings Waterfall
Invibes Advertising NV
Income Statement
Invibes Advertising NV
| Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
|
| Revenue |
10
N/A
|
10
-2%
|
12
+21%
|
17
+44%
|
23
+40%
|
28
+20%
|
28
+1%
|
27
-3%
|
29
+7%
|
28
-2%
|
27
-6%
|
25
-8%
|
|
| Gross Profit | |||||||||||||
| Cost of Revenue |
(5)
|
(5)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Gross Profit |
4
N/A
|
4
-3%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||
| Operating Expenses |
(4)
|
(4)
|
(12)
|
(17)
|
(23)
|
(29)
|
(36)
|
(34)
|
(28)
|
(29)
|
(30)
|
(29)
|
|
| Selling, General & Administrative |
(3)
|
(3)
|
(5)
|
(7)
|
(9)
|
(13)
|
(17)
|
(15)
|
(12)
|
(13)
|
(13)
|
(14)
|
|
| Depreciation & Amortization |
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(3)
|
(3)
|
(1)
|
(1)
|
(2)
|
(2)
|
|
| Other Operating Expenses |
0
|
(0)
|
(6)
|
(11)
|
(13)
|
(15)
|
(16)
|
(15)
|
(15)
|
(15)
|
(15)
|
(14)
|
|
| Operating Income |
1
N/A
|
0
-39%
|
(1)
N/A
|
(0)
+77%
|
0
N/A
|
(2)
N/A
|
(8)
-352%
|
(7)
+15%
|
1
N/A
|
(1)
N/A
|
(4)
-266%
|
(5)
-26%
|
|
| Pre-Tax Income | |||||||||||||
| Interest Income Expense |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
|
| Non-Reccuring Items |
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
(2)
|
(2)
|
|
| Total Other Income |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
1
N/A
|
0
-46%
|
(1)
N/A
|
(1)
+32%
|
0
N/A
|
(2)
N/A
|
(8)
-311%
|
(7)
+16%
|
(0)
+100%
|
(2)
-29 829%
|
(6)
-202%
|
(7)
-13%
|
|
| Net Income | |||||||||||||
| Tax Provision |
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
(0)
|
(0)
|
|
| Income from Continuing Operations |
1
|
0
|
(1)
|
(1)
|
0
|
(2)
|
(8)
|
(7)
|
1
|
(2)
|
(7)
|
(7)
|
|
| Income to Minority Interest |
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
|
| Net Income (Common) |
1
N/A
|
0
-57%
|
(1)
N/A
|
(0)
+48%
|
0
N/A
|
(2)
N/A
|
(8)
-397%
|
(7)
+16%
|
1
N/A
|
(2)
N/A
|
(7)
-328%
|
(7)
-12%
|
|
| EPS (Diluted) |
0.22
N/A
|
0.09
-59%
|
-0.25
N/A
|
-0.13
+48%
|
0.12
N/A
|
-0.34
N/A
|
-1.78
-424%
|
-1.5
+16%
|
0.13
N/A
|
-0.33
N/A
|
-1.45
-339%
|
-1.63
-12%
|
|